Bill 59: Rare Disease Strategy Act, 2025

This bill primarily affects healthcare providers, pharmaceutical companies, and biotech firms operating in Ontario that develop or distribute treatments for rare diseases. Businesses involved in rare disease drug development, diagnostic testing, and specialized medical services could see new opportunities or shifting regulatory requirements as the government implements the working group's recommendations. The impact is most relevant to mid-sized and larger companies in the life sciences and healthcare sectors, though smaller specialty pharmacies and clinical research organizations may also be affected. Day-to-day impacts could include changes to drug approval pathways, coverage and reimbursement frameworks, and how rare disease patients are diagnosed and referred for treatment in Ontario.